Cell子刊：北医三院梁晓龙团队开发新型光动力疗法，高效激活细胞焦亡，增强抗肿瘤免疫

Core Viewpoint - Tumor immunotherapy, particularly immune checkpoint blockade (ICB) targeting the PD-1/PD-L1 pathway, shows promise in treating advanced cancers but is limited by insufficient response rates. Recent findings suggest that Gasdermin D-mediated pyroptosis can trigger a robust systemic immune response, with only 15% of pyroptotic tumor cells capable of eliminating the entire tumor, presenting a new strategy for enhancing anti-tumor immunity [2][3][10]. Summary by Sections Research Development - A new self-luminous photodynamic therapy system, CC@PDC, has been developed to efficiently activate pyroptosis and stimulate anti-tumor immunity. This system, when used in conjunction with anti-PD-L1 antibodies, demonstrates superior anti-tumor and immune effects, offering a novel strategy for cancer treatment [3][10]. Mechanism and Composition - The CC@PDC system is designed with efficient resonance energy transfer, effective generation of singlet oxygen (1 O₂), and strong pyroptosis induction capabilities. It consists of amphiphilic porphyrin lipids, camptothecin derivatives, and a targeted assembly that encapsulates oleic acid-modified calcium peroxide and a specific compound to enhance its efficacy in acidic tumor microenvironments [7][10]. Key Findings - The study highlights that the camptothecin-enhanced self-luminous photodynamic chemotherapy can synergistically induce tumor cell pyroptosis and, when combined with anti-PD-L1 antibodies, significantly enhances the anti-tumor immune response, providing a promising new approach for cancer therapy [10][11].